CAR-T cell therapy: a game-changer in cancer treatment and beyond

Kumar Utkarsh, Namita Srivastava, Sachin Kumar, Azhar Khan, Gunjan Dagar, Mukesh Kumar, Mayank Singh, Shabirul Haque
{"title":"CAR-T cell therapy: a game-changer in cancer treatment and beyond","authors":"Kumar Utkarsh, Namita Srivastava, Sachin Kumar, Azhar Khan, Gunjan Dagar, Mukesh Kumar, Mayank Singh, Shabirul Haque","doi":"10.1007/s12094-023-03368-2","DOIUrl":null,"url":null,"abstract":"<p>In recent years, cancer has become one of the primary causes of mortality, approximately 10 million deaths worldwide each year. The most advanced, chimeric antigen receptor (CAR) T cell immunotherapy has turned out as a promising treatment for cancer. CAR-T cell therapy involves the genetic modification of T cells obtained from the patient's blood, and infusion back to the patients. CAR-T cell immunotherapy has led to a significant improvement in the remission rates of hematological cancers. CAR-T cell therapy presently limited to hematological cancers, there are ongoing efforts to develop additional CAR constructs such as bispecific CAR, tandem CAR, inhibitory CAR, combined antigens, CRISPR gene-editing, and nanoparticle delivery. With these advancements, CAR-T cell therapy holds promise concerning potential to improve upon traditional cancer treatments such as chemotherapy and radiation while reducing associated toxicities. This review covers recent advances and advantages of CAR-T cell immunotherapy.</p>","PeriodicalId":10166,"journal":{"name":"Clinical and Translational Oncology","volume":"117-119 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12094-023-03368-2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

In recent years, cancer has become one of the primary causes of mortality, approximately 10 million deaths worldwide each year. The most advanced, chimeric antigen receptor (CAR) T cell immunotherapy has turned out as a promising treatment for cancer. CAR-T cell therapy involves the genetic modification of T cells obtained from the patient's blood, and infusion back to the patients. CAR-T cell immunotherapy has led to a significant improvement in the remission rates of hematological cancers. CAR-T cell therapy presently limited to hematological cancers, there are ongoing efforts to develop additional CAR constructs such as bispecific CAR, tandem CAR, inhibitory CAR, combined antigens, CRISPR gene-editing, and nanoparticle delivery. With these advancements, CAR-T cell therapy holds promise concerning potential to improve upon traditional cancer treatments such as chemotherapy and radiation while reducing associated toxicities. This review covers recent advances and advantages of CAR-T cell immunotherapy.

Abstract Image

CAR-T 细胞疗法:改变癌症治疗及其他领域的游戏规则
近年来,癌症已成为导致死亡的主要原因之一,全球每年约有 1 000 万人死于癌症。最先进的嵌合抗原受体(CAR)T 细胞免疫疗法已成为治疗癌症的有效方法。CAR-T 细胞疗法包括对从患者血液中提取的 T 细胞进行基因改造,然后输回患者体内。CAR-T 细胞免疫疗法大大提高了血液肿瘤的缓解率。目前,CAR-T 细胞疗法仅限于血液癌症,但人们正在努力开发更多的 CAR 构建,如双特异性 CAR、串联 CAR、抑制性 CAR、联合抗原、CRISPR 基因编辑和纳米颗粒递送。随着这些技术的进步,CAR-T 细胞疗法有望改善化疗和放疗等传统癌症治疗方法,同时减少相关毒性。本综述将介绍 CAR-T 细胞免疫疗法的最新进展和优势。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信